Skip to main content
Top
Published in: AIDS and Behavior 6/2012

01-08-2012 | Original Paper

Measuring Adherence to Antiretroviral Treatment: The Role of Pharmacy Records of Drug Withdrawals

Authors: Eliana Battaggia Gutierrez, Ana Marli Christovam Sartori, Ana Lucia Schmidt, Bruna Mamprim Piloto, Bruna Biagi França, Adriana Santos de Oliveira, Adriana Rodrigues Pouza, Roberta Vilela Moreno, Camila de Melo Picone, Manoel Carlos Sampaio de Almeida Ribeiro

Published in: AIDS and Behavior | Issue 6/2012

Login to get access

Abstract

This study aimed to evaluate adherence to antiretroviral treatment (ART) among HIV + adults, assess its association with HIV viral load (VL) and identify factors associated to adherence. A survey involving a random sample of adults followed at a HIV/AIDS reference center in São Paulo city, Brazil, from 2007 to 2009 was done. A questionnaire was applied and data were retrieved from the pharmacy and medical records. The study involved 292 subjects: 70.2% men; median age: 43 years; median duration of ART: 8 years. 89.3% self-reported taken all prescribed pills in the last 3 days but only 39.3% picked up ≥95% of the prescribed ART from the pharmacy in the last 12 months. At the multivariate analysis having symptoms prior to ART, taking fewer ART pills, and not missing medical appointments were independently associated to higher adherence. Adherence was strongly associated with undetectable HIV VL. Rates of undetectable HIV VL did not differ from 80 to ≥95% of adherence.
Literature
2.
go back to reference Rocha GM, Machado CJ, Acurcio FA, Guimaraes MDC. Monitoring adherence to antiretroviral treatment in Brazil: an urgent challenge. Cad Saude Publica. 2011;27(Suppl 1):S67–78.PubMedCrossRef Rocha GM, Machado CJ, Acurcio FA, Guimaraes MDC. Monitoring adherence to antiretroviral treatment in Brazil: an urgent challenge. Cad Saude Publica. 2011;27(Suppl 1):S67–78.PubMedCrossRef
3.
go back to reference Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–8.PubMedCrossRef Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–8.PubMedCrossRef
4.
go back to reference Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–8.PubMedCrossRef Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–8.PubMedCrossRef
5.
go back to reference Taiwo B. Adherence to antiretroviral therapy: the more you look, the more you see. Curr Opin HIV AIDS. 2009;4:488–92.PubMedCrossRef Taiwo B. Adherence to antiretroviral therapy: the more you look, the more you see. Curr Opin HIV AIDS. 2009;4:488–92.PubMedCrossRef
6.
go back to reference Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.PubMedCrossRef Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.PubMedCrossRef
7.
go back to reference Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.PubMed Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.PubMed
8.
go back to reference Bonolo PF, Gomes RRFM, Guimarães MDC. Adherence to antiretroviral treatment (HIV/AIDS): associated factors and adherence measures. Epidemiologia e Serviços de Saúde. 2007;16:251–9. Bonolo PF, Gomes RRFM, Guimarães MDC. Adherence to antiretroviral treatment (HIV/AIDS): associated factors and adherence measures. Epidemiologia e Serviços de Saúde. 2007;16:251–9.
9.
go back to reference Polejack L, Seidl EM. Monitoring and evaluation of adherence to ARV treatment for HIV/AIDS: challenges and possibilities. Cien Saude Colet. 2010;15(Suppl 1):1201–8.PubMedCrossRef Polejack L, Seidl EM. Monitoring and evaluation of adherence to ARV treatment for HIV/AIDS: challenges and possibilities. Cien Saude Colet. 2010;15(Suppl 1):1201–8.PubMedCrossRef
10.
go back to reference Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9:238–46.PubMedCrossRef Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9:238–46.PubMedCrossRef
11.
go back to reference McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52:493–506.PubMedCrossRef McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52:493–506.PubMedCrossRef
12.
go back to reference Gomes RRFM, Machado CJ, Acurcio FA, Guimaraes MDC. Pharmacy records as an indicator of non-adherence to antiretroviral therapy by HIV-infected patients. Cad Saude Publica. 2009;25:495–506.PubMed Gomes RRFM, Machado CJ, Acurcio FA, Guimaraes MDC. Pharmacy records as an indicator of non-adherence to antiretroviral therapy by HIV-infected patients. Cad Saude Publica. 2009;25:495–506.PubMed
13.
go back to reference Bonolo Pde F, Machado CJ, Cesar CC, Ceccato MG, Guimaraes MD. Vulnerability and non-adherence to antiretroviral therapy among HIV patients, Minas Gerais State, Brazil. Cad Saude Publica. 2008;24:2603–13.PubMedCrossRef Bonolo Pde F, Machado CJ, Cesar CC, Ceccato MG, Guimaraes MD. Vulnerability and non-adherence to antiretroviral therapy among HIV patients, Minas Gerais State, Brazil. Cad Saude Publica. 2008;24:2603–13.PubMedCrossRef
14.
go back to reference Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS. 2004;18(Suppl 3):S15–20.PubMedCrossRef Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS. 2004;18(Suppl 3):S15–20.PubMedCrossRef
15.
go back to reference Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21:1579–89.PubMedCrossRef Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21:1579–89.PubMedCrossRef
16.
go back to reference Blatt CR, Citadin CB, Souza FG, Mello RS, Galato D. Assessment of adherence to antiretroviral drugs in a municipality in southern Brazil. Rev Soc Bras Med Trop. 2009;42:131–6.PubMedCrossRef Blatt CR, Citadin CB, Souza FG, Mello RS, Galato D. Assessment of adherence to antiretroviral drugs in a municipality in southern Brazil. Rev Soc Bras Med Trop. 2009;42:131–6.PubMedCrossRef
17.
go back to reference Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
18.
go back to reference Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRef Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRef
19.
go back to reference Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45:4–8.PubMedCrossRef Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45:4–8.PubMedCrossRef
20.
go back to reference Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45:372–9.PubMedCrossRef Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45:372–9.PubMedCrossRef
21.
go back to reference Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50:1192–7.PubMedCrossRef Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50:1192–7.PubMedCrossRef
22.
go back to reference Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009;4:e7196.PubMedCrossRef Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009;4:e7196.PubMedCrossRef
Metadata
Title
Measuring Adherence to Antiretroviral Treatment: The Role of Pharmacy Records of Drug Withdrawals
Authors
Eliana Battaggia Gutierrez
Ana Marli Christovam Sartori
Ana Lucia Schmidt
Bruna Mamprim Piloto
Bruna Biagi França
Adriana Santos de Oliveira
Adriana Rodrigues Pouza
Roberta Vilela Moreno
Camila de Melo Picone
Manoel Carlos Sampaio de Almeida Ribeiro
Publication date
01-08-2012
Publisher
Springer US
Published in
AIDS and Behavior / Issue 6/2012
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0168-3

Other articles of this Issue 6/2012

AIDS and Behavior 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine